Synergistic effect of angiotensin II on vascular endothelial growth factor-A-mediated differentiation of bone marrow-derived mesenchymal stem cells into endothelial cells

被引:30
作者
Ikhapoh, Izuagie Attairu [1 ]
Pelham, Christopher J. [2 ]
Agrawal, Devendra K. [1 ,2 ,3 ]
机构
[1] Creighton Sch Med, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA
[2] Creighton Sch Med, Dept Biomed Sci, Omaha, NE 68178 USA
[3] Creighton Sch Med, Ctr Clin & Translat Sci, Omaha, NE 68178 USA
基金
美国国家卫生研究院;
关键词
NITRIC-OXIDE; MYOCARDIAL-INFARCTION; SIGNAL-TRANSDUCTION; HEART-DISEASE; RECEPTOR; VEGF; PROLIFERATION; MECHANISMS; EXPRESSION; UPDATE;
D O I
10.1186/scrt538
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Introduction: Increased levels of angiotensin II (Ang II) and activity of Ang II receptor type 1 (AT1R) elicit detrimental effects in cardiovascular disease. However, the role of Ang II receptor type 2 (AT2R) remains poorly defined. Mesenchymal stem cells (MSCs) replenish and repair endothelial cells in the cardiovascular system. Herein, we investigated a novel role of angiotensin signaling in enhancing vascular endothelial growth factor (VEGF)-A-mediated differentiation of MSCs into endothelial cells (ECs). Methods: Bone marrow was aspirated from the femurs of Yucatan microswine. MSCs were extracted via ficoll density centrifugation technique and were strongly immunopositive for MSC markers, CD44, CD90, and CD105, but negative for hematopoietic markers, CD14 and CD45. Subsequently, naive MSCs were differentiated for 10 days in varying concentrations and combinations of VEGF-A, Ang II, and AT1R or AT2R antagonists. Markers specific to ECs were determined by FACS analysis. Results: AT1R and AT2R expression and cellular localization was demonstrated in MSCs stimulated with VEGF-A and Ang II via quantitative RT-PCR and immunofluorescence, respectively. Differentiation of naive MSCs in media containing Ang II (2 ng/ml) plus low-dose VEGF-A (2 ng/ml) produced a significantly higher percentage of cells that were positive for expression of EC markers (for example, platelet endothelial cell adhesion molecule, vascular endothelial Cadherin and von Willebrand factor) compared to VEGF-A alone. Ang II alone failed to induce EC marker expression. MSCs differentiated with the combination of Ang II and VEGF-A were capable of forming capillary tubes using an in vitro angiogenesis assay. Induction of EC marker expression was greatly attenuated by co-treatment of Ang II/VEGF-A with the AT2R antagonist PD123319, but not the AT1R antagonist telmisartan. Conclusions: We report the presence of functional AT2R receptor on porcine bone marrow-derived MSCs, where it positively regulates EC differentiation. These findings have significant implications toward therapeutic approaches based on activation of AT2R, which could be a means to stimulate regeneration of damaged endothelium and prevent vascular thrombosis.
引用
收藏
页数:13
相关论文
共 41 条
[1]   Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy [J].
Ambasta, Rashmi K. ;
Sharma, Archita ;
Kumar, Pravir .
VASCULAR CELL, 2011, 3
[2]  
Baijun K, 2007, VASC PHARMACOL, V47, P199
[3]  
Burdon TJ, 2011, J CELL MOL MED, V5, P1032
[4]   Vascular endothelial growth factor-induced endothelial cell proliferation is regulated by interaction between VEGFR-2, SH-PTP1 and eNOS [J].
Cai, J ;
Jiang, WG ;
Ahmed, A ;
Boulton, M .
MICROVASCULAR RESEARCH, 2006, 71 (01) :20-31
[5]   Angiotensin H modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium [J].
Carbajo-Lozoya, Javier ;
Lutz, Susanne ;
Feng, Yuxi ;
Kroll, Jens ;
Hammes, Hans-Peter ;
Wieland, Thomas .
CELLULAR SIGNALLING, 2012, 24 (06) :1261-1269
[6]  
Carey RM, 2006, ACTA PHYSL SCAND, V168, P65
[7]   Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis [J].
Clere, Nicolas ;
Corre, Isabelle ;
Faure, Sebastien ;
Guihot, Anne-Laure ;
Vessieres, Emilie ;
Chalopin, Marie ;
Morel, Alain ;
Coqueret, Olivier ;
Hein, Lutz ;
Delneste, Yves ;
Paris, Francois ;
Henrion, Daniel .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (10) :2279-2291
[8]   Endothelial cells and VEGF in vascular development [J].
Coultas, L ;
Chawengsaksophak, K ;
Rossant, J .
NATURE, 2005, 438 (7070) :937-945
[9]   ACE inhibitors in heart failure: What more do we need to know? [J].
Demers C. ;
Mody A. ;
Teo K.K. ;
McKelvie R.S. .
American Journal of Cardiovascular Drugs, 2005, 5 (6) :351-359
[10]   Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent [J].
Doostzadeh, Julie ;
Clark, Lee N. ;
Bezenek, Susan ;
Pierson, Wesley ;
Sood, Poornima R. ;
Sudhir, Krishnankutty .
CORONARY ARTERY DISEASE, 2010, 21 (01) :46-56